Marksans Pharma Limited (NSE: MARKSANS)

Marksans Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	-	4,033	3,824	2,064	2,122	937.27
Short-Term Investments	-	2,710	3,328	1,399	-	-
Trading Asset Securities	-	269.94	5.4	4.35	2.61	-
Cash & Short-Term Investments	7,006	7,013	7,158	3,467	2,124	937.27
Cash Growth	-2.13%	-2.03%	106.47%	63.19%	126.66%	179.46%
Accounts Receivable	-	4,532	4,168	3,948	2,719	2,434
Other Receivables	-	106.62	48.5	43.7	1.02	-
Receivables	-	4,638	4,217	3,991	2,721	2,434
Inventory	-	6,179	4,847	4,244	4,043	2,418
Prepaid Expenses	-	251.26	198.04	159.83	-	-
Other Current Assets	-	543.05	332.57	149.34	140.04	146.66
Total Current Assets	-	18,625	16,753	12,012	9,028	5,936
Property, Plant & Equipment	-	6,811	3,869	3,423	2,540	2,300
Long-Term Investments	-	1.68	-	-	-	-
Goodwill	-	394.99	384.89	300.25	195.86	243.76
Other Intangible Assets	-	647.62	707.97	585.69	474.36	483.27
Long-Term Deferred Tax Assets	-	-	-	38.57	7.99	6.34
Other Long-Term Assets	-	329.41	189.13	41.62	41.58	57.29
Total Assets	-	26,810	21,904	16,401	12,288	9,027
Accounts Payable	-	2,683	2,306	2,001	1,687	1,103
Accrued Expenses	-	442.56	220.96	131.01	103.53	77.89
Short-Term Debt	-	290.91	415.88	362.92	187.4	188.43
Current Portion of Long-Term Debt	-	-	-	50	-	0.46
Current Portion of Leases	-	249.51	156.68	280.52	60.37	32.41
Current Income Taxes Payable	-	199.08	252.78	173.27	300.21	118.57
Other Current Liabilities	-	33.66	57.59	563.67	651.52	766.5
Total Current Liabilities	-	3,898	3,410	3,562	2,990	2,288
Long-Term Debt	-	-	-	-	50	50
Long-Term Leases	-	1,900	656.89	414.34	93.26	75.2
Long-Term Deferred Tax Liabilities	-	106.2	153.86	176.21	80.63	107.94
Other Long-Term Liabilities	-	6.63	9.3	2.83	6.94	3.23
Total Liabilities	-	5,950	4,253	4,171	3,235	2,535
Common Stock	-	453.16	453.16	409.31	409.31	409.31
Additional Paid-In Capital	-	5,045	5,045	1,732	1,751	1,751
Retained Earnings	-	13,827	10,913	8,230	6,487	3,988
Comprensive Income & Other	-	1,326	1,040	1,651	217.68	211.05
Total Common Equity	20,651	20,651	17,452	12,023	8,865	6,360
Minority Interest	-	208.52	199.1	207.01	188.57	131.1
Shareholders' Equity	20,859	20,859	17,651	12,230	9,054	6,491
Total Liabilities & Equity	-	26,810	21,904	16,401	12,288	9,027
Total Debt	2,441	2,441	1,229	1,108	391.03	346.5
Net Cash (Debt)	4,565	4,572	5,929	2,359	1,733	590.77
Net Cash Growth	-23.00%	-22.88%	151.30%	36.10%	193.41%	-
Net Cash Per Share	10.06	10.09	14.27	5.76	4.23	1.44
Filing Date Shares Outstanding	452.82	453.16	453.16	409.31	409.31	409.31
Total Common Shares Outstanding	452.82	453.16	453.16	409.31	409.31	409.31
Working Capital	-	14,726	13,343	8,450	6,039	3,648
Book Value Per Share	45.63	45.57	38.51	29.37	21.66	15.54
Tangible Book Value	19,608	19,608	16,359	11,137	8,195	5,633
Tangible Book Value Per Share	43.33	43.27	36.10	27.21	20.02	13.76
Land	-	5.18	5.1	4.67	4.14	4.14
Buildings	-	2,287	1,633	1,511	1,318	1,259
Machinery	-	4,445	3,355	3,038	2,515	2,237
Construction In Progress	-	53.81	72.46	6.95	56	-
Leasehold Improvements	-	105.64	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.